Medistim Management
Management criteria checks 4/4
Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 13.17 years. total yearly compensation is NOK6.40M, comprised of 44.2% salary and 55.8% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth NOK16.40M. The average tenure of the management team and the board of directors is 12.3 years and 9.2 years respectively.
Key information
Kari Krogstad
Chief executive officer
NOK 6.4m
Total compensation
CEO salary percentage | 44.2% |
CEO tenure | 13.2yrs |
CEO ownership | 0.3% |
Management average tenure | 12.3yrs |
Board average tenure | 9.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2022 | n/a | n/a | NOK 98m |
Jun 30 2022 | n/a | n/a | NOK 92m |
Mar 31 2022 | n/a | n/a | NOK 93m |
Dec 31 2021 | NOK 6m | NOK 3m | NOK 91m |
Sep 30 2021 | n/a | n/a | NOK 88m |
Jun 30 2021 | n/a | n/a | NOK 84m |
Mar 31 2021 | n/a | n/a | NOK 70m |
Dec 31 2020 | NOK 6m | NOK 3m | NOK 69m |
Sep 30 2020 | n/a | n/a | NOK 71m |
Jun 30 2020 | n/a | n/a | NOK 74m |
Mar 31 2020 | n/a | n/a | NOK 75m |
Dec 31 2019 | NOK 4m | NOK 3m | NOK 70m |
Sep 30 2019 | n/a | n/a | NOK 79m |
Jun 30 2019 | n/a | n/a | NOK 73m |
Mar 31 2019 | n/a | n/a | NOK 64m |
Dec 31 2018 | NOK 4m | NOK 2m | NOK 57m |
Sep 30 2018 | n/a | n/a | NOK 46m |
Jun 30 2018 | n/a | n/a | NOK 48m |
Mar 31 2018 | n/a | n/a | NOK 45m |
Dec 31 2017 | NOK 4m | NOK 2m | NOK 48m |
Sep 30 2017 | n/a | n/a | NOK 41m |
Jun 30 2017 | n/a | n/a | NOK 39m |
Mar 31 2017 | n/a | n/a | NOK 41m |
Dec 31 2016 | NOK 3m | NOK 2m | NOK 39m |
Sep 30 2016 | n/a | n/a | NOK 45m |
Jun 30 2016 | n/a | n/a | NOK 45m |
Mar 31 2016 | n/a | n/a | NOK 43m |
Dec 31 2015 | NOK 3m | NOK 2m | NOK 40m |
Compensation vs Market: Kari's total compensation ($USD642.44K) is below average for companies of similar size in the UK market ($USD1.02M).
Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.
CEO
Kari Krogstad (58 yo)
13.2yrs
Tenure
NOK 6,395,468
Compensation
Ms. Kari Eian Krogstad serves as Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President. Ms. Krogst...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & President | 13.2yrs | NOK 6.40m | 0.35% NOK 16.4m | |
Chief Financial Officer | no data | NOK 2.00m | 0.14% NOK 6.7m | |
Vice President of Operations & Manufacturing | no data | NOK 1.43m | no data | |
Vice President of Marketing | 12.3yrs | NOK 1.49m | 0.0036% NOK 170.3k | |
Vice President of Sales | 12.3yrs | NOK 1.71m | 0.070% NOK 3.3m | |
Chief Innovation Officer | 3.6yrs | NOK 1.41m | 0.024% NOK 1.1m | |
CEO of Medistim Norge AS & MD of Medistim Norge AS | no data | NOK 1.40m | 0.0073% NOK 340.6k | |
President of Medistim USA Inc | no data | NOK 2.86m | 0.011% NOK 511.3k | |
Country Manager of Medistim Deutschland GmbH | no data | NOK 1.68m | no data |
12.3yrs
Average Tenure
58yo
Average Age
Experienced Management: MEDIO's management team is seasoned and experienced (12.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Deputy Chairman | 2.6yrs | no data | no data | |
Chairman | 22.8yrs | NOK 400.00k | no data | |
Independent Director | 12.8yrs | NOK 225.00k | 0.0019% NOK 90.1k | |
Independent Director | 9.6yrs | NOK 225.00k | 0.011% NOK 514.1k | |
Independent Director | 8.8yrs | NOK 225.00k | no data | |
Director | less than a year | no data | no data |
9.2yrs
Average Tenure
64yo
Average Age
Experienced Board: MEDIO's board of directors are considered experienced (9.2 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/11/16 13:47 |
End of Day Share Price | 2022/08/19 00:00 |
Earnings | 2022/09/30 |
Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medistim ASA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Magnus Granerød | Beringer Finance AB |
Karl Norén | Danske Bank |
Simen Mortensen | DNB Markets |